EUVIMEDEUVIMED entdecken
Crossref

Astrocytic networks as a novel therapeutic target in Parkinson’s disease

Nataly Hastings, S.M. Jamshedur Rahman, Przemysław Stempor, Kuan, William, Maha Alfaidi, Matthew Thomas Wayland, Aleksandr Zakirov, Michael Whitehead, Kotter, Mark

Apollo (University of Cambridge) · 25.07.2023

DOI: 10.17863/cam.99937 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Apollo (University of Cambridge), erschienen am 25.07.2023. Verfasst von Nataly Hastings und 10 weiteren Autor:innen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Parkinson’s disease (PD) is a neurodegenerative condition with the highest rise in disability and is currently incurable. Dopamine replacement therapies reduce motor symptoms temporarily, but do not address non-motor symptoms (NMS) of PD, and often cause serious side effects; with up to 10 million people with PD worldwide and predicted economic burden of over £79 billion in the US alone by 2037, the unmet clinical need is large. Deeper understanding of PD pathology is required to create new transformative therapies. One cell type that received increasing attention in PD recently is astrocytes. Astrocytes express multiple familial PD-associated genes as much, or more than neurones, and develop alpha-synuclein (a-syn) immunoreactivity which correlates with dopaminergic loss. Their causal involvement in PD symptom development was demonstrated in vitro and in vivo, where healthy astrocytes could rescue functions of neurones carrying PD mutations and reduce motor symptoms in rodent models, and diseased astrocytes could induce PD-resembling dysfunction in heathy neurones or animal models. A key aspect of astrocyte biology is their ability to form large networks transmitting calcium signals. Abnormal calcium signalling is also a hallmark of PD. We hypothesised that astrocyte networks are dysregulated in PD, and normalising calcium transmission in astrocyte networks could reduce a-syn aggregation and inflammation. Our first target is connexin43 (Cx43) which connects astrocytes via gap junctions (GJs) and promotes calcium transmission, and dysregulation of which is linked to inflammasome activation through hemichannel (HC) opening.

Schlagwörter

Parkinson's diseaseastrocytesastrocyte networksalpha-synuclein aggregationcalcium signalingconnexin 43gap junctionshemichannelsinflammasome activationnon-motor symptoms

Zitieren

APA

Hastings, N., Rahman, S. J., Stempor, P., Kuan, William, Alfaidi, M., Wayland, M. T., Zakirov, A., Whitehead, M., Kotter, & Mark (2023). Astrocytic networks as a novel therapeutic target in Parkinson’s disease. Apollo (University of Cambridge). https://doi.org/10.17863/cam.99937

Vancouver

Hastings N, Rahman SJ, Stempor P, Kuan, William, Alfaidi M, et al. Astrocytic networks as a novel therapeutic target in Parkinson’s disease. Apollo (University of Cambridge). 2023. doi:10.17863/cam.99937

BibTeX
@article{Hastings2023,
  author = {Hastings, Nataly and Rahman, S.M. Jamshedur and Stempor, Przemysław and Kuan and William and Alfaidi, Maha and Wayland, Matthew Thomas and Zakirov, Aleksandr and Whitehead, Michael and Kotter and Mark},
  title = {Astrocytic networks as a novel therapeutic target in Parkinson’s disease},
  journal = {Apollo (University of Cambridge)},
  year = {2023},
  doi = {10.17863/cam.99937}
}
Kostenlos starten →